Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mixed amphetamine salts (Richwood Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mixed amphetamine salts is a central nervous system (CNS) stimulant medication primarily used for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It consists of a specific combination of four amphetamine salts: dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate. This combination results in a 3:1 ratio of d-amphetamine to l-amphetamine. The drug acts as a sympathomimetic amine that increases the synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic neurons. It is available in various formulations, including immediate-release tablets and several extended-release versions designed for once-daily dosing.
- Brand names
- AdderallAdderall XRMydayisAdzenys XR-ODTAdzenys ERDyanavel XR
- Other names
- MASamphetamine mixed saltsdextroamphetamine saccharate + amphetamine aspartate + dextroamphetamine sulfate + amphetamine sulfate
02
Targets
NET (Norepinephrine Transporter)TAAR1 (Trace amine-associated receptor 1)DAT (Dopamine plasma membrane transport protein)VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on mixed amphetamine salts (Richwood Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mixed amphetamine salts (Richwood Pharmaceuticals).